Pharmacokinetic and Metabolism of [14^C] BMS-986177 in Healthy Male Participants

• Status: Completed
• Trial end date: 2019-07-11
• Target enrollment: 0
• Participant gender: Male

Summary

This is an ADME study. Human radiolabeled mass balance studies are performed as part of drug development to obtain information about the absorption, distribution, metabolism, and excretion (ADME) of a study treatment. The goals of human ADME studies include the assessment of absorption, distribution, routes and rates of excretion, mass balance, and metabolite profile and identification.

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Bristol-Myers Squibb

Criteria

Inclusion Criteria:

• Signed ICF

• Healthy Male

• Body mass index of 18.0 to 32.0 kg/m2, inclusive.

• Agreement to use approved contraception for 94 days post treatment

• Agreement to not donate sperm for 94 days post treatment

Exclusion Criteria:

• Acute or chronic illness

• GI disease current or recent

• History of dizziness or recurring headaches

• Head injury within last 2 years

• GI surgery

• History or evidence of abnormal bleeding